It has not demonstrated greater efficacy than other antipsychotics and its safety profile is similar to other second generation antipsychotics (higher frequency of akathisia and somnolence).
Given its high potential for drug interactions, the need for adjustment in renal and hepatic impairment and the importance of taking it with meals, it isn’t considered an advance in the treatment of schizophrenia.